At SpotitEarly, we’re transforming the way screening works, not the way cancer is detected, because early diagnosis helps save lives and reduces treatment costs. Our unique approach tackles the global challenge of early-stage cancer diagnoses and offers a much more effective way to screen for the disease.
Across the four most common types of cancer, our results are exceptional. In recent tests, SpotitEarly’s non-invasive, scalable and cost-effective screening solution delivered exceptional accuracy, detecting cancer with 93.9% sensitivity and 94.3% specificity.
At the heart of our solution is LUCID, an advanced digital platform that fuses the extraordinary scent-detection abilities of trained dogs with cutting-edge AI precision. From easy, pain-free breath sample collection to real-time data analysis, SpotitEarly delivers highly accurate, actionable screening results that set new quality standards in healthcare.
ALL RIGHTS RESERVED, SPOTITEARLY 2025
SpotitEarly tests are not intended to replace current screening procedures, but rather to be used as an additional pre-screening layer to complement preventative protocols already in place.
The SpotitEarly tests have not been approved by the Food and Drug Administration (FDA) and are currently under development and validation.
